Interferon Beta-1A

• DESIRE MS: A prospective randomized non-inferiority trial comparing anti-CD20 maintenance versus De-Escalation Strategy In Relapsing-Remitti… Pending
  2024-513292-40-00 Phase III 1 country Centre Hospitalier Universitaire De Montpellier
• Nivolumab in combination with cisplatin and 5-fluorouracil as induction therapy in children and adults with EBV-positive nasopharyngeal carc… Recruiting
  2022-500676-59-00 Phase II 1 country GPOH gGmbH
• DISEASE MODIFYING THERAPIES WITHDRAWAL IN INACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS AGED 55 AND OVER: A MULTICENTRIC, RANDOMI… Recruiting
  2024-513475-41-00 Phase III 1 country Les Hopitaux Universitaires De Strasbourg
• Metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration: a phase IIb triple-blind placeb… Ended
  2023-503190-38-00 Phase II 1 country Antwerp University Hospital
• A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon beta-1a) in Pediatric Participants for the Treatment of… Ended
  2023-505624-56-00 Phase III 5 countries Biogen Idec Research Limited
• STOP-I-SEP_Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Ended
  2024-516628-32-00 Phase III 1 country Centre Hospitalier Universitaire De Rennes
• Study of efficacy and tolerability of ofatumumab vs. First Line disease modifying treatment (DMT) - physician’s choice in the treatment of n… Ended
  2023-507431-37-00 Phase III 4 countries Novartis Pharma AG
• Phase 2 study of inhaled SNG001 in mechanically ventilated patients with respiratory virus infection Ended
  2024-520375-27-00 Phase II 4 countries Synairgen Research Limited

Showing 1–8 of 8 trials